Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • Transdermal PTEN mRNA Delivery via HA-LNPs for Melanoma Ther

    2026-05-29

    Transdermal Delivery of PTEN mRNA with Hyaluronated Lipid Nanoparticles: Advancing Melanoma Immunotherapy

    Study Background and Research Question

    Melanoma remains one of the most aggressive and treatment-resistant forms of skin cancer, characterized by late diagnosis, high metastatic potential, and suboptimal response rates to existing therapies. Immune checkpoint inhibitors (ICIs), such as anti-PD-1 and anti-CTLA-4 antibodies, have improved clinical outcomes for some patients, yet resistance—often mediated by tumor-intrinsic factors—remains a major challenge. Loss or mutation of the tumor suppressor gene PTEN is a recurrent event in melanoma and other cancers, contributing to unchecked cellular proliferation, PI3K/Akt signaling pathway activation, and immune evasion by impairing T cell infiltration and cytotoxicity. Restoring PTEN function has emerged as a promising strategy to counteract these mechanisms, but traditional gene delivery methods face significant drawbacks, including risk of genomic integration, immunogenicity, and inefficient cytosolic delivery. The reference study (Kim et al., J. Control. Release 2026) posed the central question: Can a non-invasive, targeted, and biocompatible delivery system for PTEN mRNA effectively restore tumor suppressor activity and overcome immune resistance in melanoma?

    Key Innovation from the Reference Study

    The study by Kim et al. introduces a novel platform: hyaluronate-conjugated lipid nanoparticles (HA-LNPs) designed for transdermal mRNA delivery. By integrating hyaluronate (HA) directly into the lipid bilayer using HA-dimyristoyl glycerol (HA-DMG), the resulting nanoparticles achieve several objectives:
    • Elimination of poly(ethylene glycol) (PEG) from the formulation, addressing concerns of PEG-induced immunogenicity and anaphylaxis.
    • Stable surface presentation of HA moieties, promoting CD44-mediated targeting and efficient skin/tumor penetration.
    • Enhanced encapsulation and protection of large mRNA payloads, specifically PTEN mRNA.
    This approach leverages the abundant expression of CD44 on melanoma and skin-resident cells, enabling efficient, localized, and non-invasive tumor suppressor gene mRNA delivery.

    Methods and Experimental Design Insights

    Kim et al. developed HA-LNPs by self-assembly of lipid mixtures containing HA-DMG, which integrates uniformly into the nanoparticle structure. The use of HA as both a stabilizing and targeting ligand eliminates the need for post-formulation surface modifications. PTEN mRNA was encapsulated during the nanoparticle assembly process, resulting in uniformly sized particles suitable for skin application. In vitro experiments assessed the uptake of PTEN mRNA-loaded HA-LNPs (PTEN mRNA@HA-LNP) by CD44-expressing melanoma cells, restoration of PTEN expression, induction of immunogenic cell death (ICD), and effects on cell viability. In vivo, the transdermal application of these nanoparticles was evaluated in a melanoma mouse model, with analyses focused on skin/tumor penetration, restoration of PTEN function, tumor growth inhibition, immune activation, and systemic toxicity.

    Protocol Parameters

    • HA-LNP formulation: Incorporate HA-DMG into the lipid mixture for self-assembly; optimize HA content for maximal CD44 targeting and particle stability.
    • mRNA encapsulation: Encapsulate full-length PTEN mRNA during nanoparticle assembly; confirm encapsulation efficiency and mRNA integrity.
    • Transdermal application: Apply HA-LNP suspension topically to the tumor-bearing skin region in animal models; monitor for penetration, distribution, and therapeutic efficacy.
    • Immune and tumor response monitoring: Assess PTEN protein restoration, ICD markers (e.g., calreticulin exposure), T cell infiltration, and tumor burden over time.

    Core Findings and Why They Matter

    The study demonstrated that PTEN mRNA@HA-LNPs:
    • Efficiently restored PTEN expression in melanoma cells in vitro, reversing the PI3K/Akt-driven survival and proliferation phenotype.
    • Induced immunogenic cell death, as evidenced by upregulation of ICD markers and reduced melanoma cell viability.
    • Achieved deep skin and tumor penetration following topical application in vivo, with significant restoration of PTEN protein in tumor tissue.
    • Suppressed tumor growth and improved immune activation, with increased T cell infiltration and minimal systemic toxicity (Kim et al., 2026).
    These results underscore the potential of HA-LNPs as a clinically translatable vehicle for localized, mRNA-based immunotherapy, overcoming key challenges associated with systemic delivery and immunogenic vectors. By targeting the tumor microenvironment directly and restoring intrinsic tumor suppressor activity, this strategy addresses both tumor-intrinsic and immune-mediated resistance mechanisms.

    Comparison with Existing Internal Articles

    Several recent internal reviews have highlighted the importance of high-quality, Cap 1-structured tumor suppressor gene mRNA in cancer research and gene therapy workflows. For example, "EZ Cap™ Human PTEN mRNA: Advancing mRNA-Based Tumor Immunotherapy" discusses the advantages of using Cap 1-modified, poly(A)-tailed PTEN mRNA for robust expression and immune evasion minimization in preclinical models. Similarly, "Transdermal Delivery of PTEN mRNA via HA-LNPs for Melanoma Immunotherapy" reviews the technical advances and translational relevance of the reference paper's HA-LNP platform. While these articles emphasize the enabling properties of synthetic mRNA for PI3K/Akt pathway modulation and tumor suppressor restoration, the reference study provides direct experimental evidence for the superior biocompatibility, skin penetration, and immune activation achieved with the HA-LNP approach. The integration of HA as both stabilizer and targeting ligand marks a significant step forward compared to earlier PEGylated or non-targeted LNP systems discussed in prior reviews.

    Limitations and Transferability

    Despite its promising results, the study's primary limitations include its focus on preclinical melanoma models and the use of immunocompetent mice, which may not fully recapitulate the complexity of human skin structure, tumor heterogeneity, or immune contexture. Long-term safety, dosing frequency, and scalability for clinical manufacturing remain to be validated. Additionally, while the HA-LNP platform demonstrated enhanced targeting of CD44-expressing cells, potential off-target effects in skin or systemic tissues will require further investigation. The approach is likely transferable to other skin-associated malignancies expressing CD44 or amenable to transdermal intervention, but its efficacy in non-skin tumors or metastatic disease remains untested. The use of chemically modified mRNA and HA-LNPs may also be extended to other tumor suppressor genes or immune-modulatory transcripts, though this will depend on disease-specific biology and delivery barriers.

    Research Support Resources

    For researchers seeking to replicate or extend these workflows, high-quality, in vitro transcribed mRNA with optimized capping and stability features is essential. The EZ Cap™ Human PTEN mRNA (SKU R1025) offers a validated, Cap 1-structured, poly(A)-tailed mRNA encoding the full-length human PTEN tumor suppressor. This reagent is suitable for nanoparticle encapsulation, mRNA transfection and expression studies, and preclinical gene therapy research, as outlined in both the reference study and internal reviews. Proper handling and storage protocols should be followed to maintain mRNA integrity and maximize experimental reproducibility.